CVS Health is rolling out new digital tools for its pharmacy benefit manager clients to manage pharmacy benefits and monitor prescription spending, citing a new CVS Caremark survey showing employers have higher trust in PBMs to manage drug costs and access to complex treatments. The company is also expanding coverage for biosimilars and GLP-1 therapies across its pharmacy network with a focus on affordability, aiming to support employers and payers facing rising specialty drug spending. The rollout follows second-quarter 2026 results that showed revenue of US$106.10 billion and net income of US$2.98 billion, along with an increase in 2026 GAAP diluted EPS guidance to a range of US$6.84 to US$7.04. Investors will watch for PBM client retention, GLP-1 prescription trends, and any revision to the 2026 earnings guidance or the revenue outlook of at least US$414.0 billion.
CVS Health CorpNew PBM tools and expanded biosimilar/GLP-1 coverage aim to boost client retention and address rising specialty drug spending, supporting demand for CVS's PBM services.
